Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Topical Lidocaine and Bupivacaine Alone | In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine | 0 | None | 0 | 8 | 0 | 8 | View |
| Topical Lidocaine and Bupivacaine With Thrombin | In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin | 0 | None | 0 | 6 | 0 | 6 | View |
| Topical Lidocaine and Bupivacaine With Thrombin and Tranexamic Acid | In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 500 mg of tranexamic acid | 0 | None | 0 | 5 | 0 | 5 | View |
| Topical Lidocaine and Bupivacaine With Thrombin and Aminocaproic Acid | In this treatment group, each solution will include 5 ml of 1% lidocaine, 5 ml of 0.25% bupivacaine, 10000 units of thrombin, and 1000 mg of aminocaproic acid | 0 | None | 0 | 6 | 0 | 6 | View |